Main Menu

Landos Biopharma, Inc.


Rigrodsky Law, P.A. is investigating Landos Biopharma, Inc. (“Landos”) regarding possible breaches of fiduciary duties and other violations of law related to Landos’s agreement to be acquired by AbbVie Inc. Under the terms of the agreement, Landos shareholders will receive $20.42 per share in cash upon closing, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, subject to the achievement of a clinical development milestone.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 04/25/2024

* Indicates a required field.

Back to Page